A Peek at CMO East 2013

Uploaded on


More in: Business
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads


Total Views
On Slideshare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. Development Process: Plan with the End in Mind Commercialization NDA (BLA)/MAA Submission(s) Registration Strategy Integrated Summaries Final Reports Study Conduct Protocols Protocol Outlines Clinical Development Plan Non-Clinical Plan 1  
  • 2. Drug Development Regulatory Provisions §  Fast Track Development Status - To expedite product development §  Orphan Drug Status - To encourage development of drugs for rare diseases §  Accelerated Approval - To speed approval in a life-threatening disease based on surrogate marker data with a commitment to conduct confirmatory studies §  Key Consideration - Benefit risk assessment 2  
  • 3. Drug Development Imperative: Prepara&on  of  Target  Product  Profile   §  Considerations –  Indications –  Target patient populations –  Efficacy profile –  Safety profile –  Formulations –  Dosage regimens 3  
  • 4. Input Into Drug Development Program §  Involve Constituencies   -­‐  Regulatory Agencies -­‐  Key Investigators & Opinion Leaders (KOLs) -­‐  Patient Advocacy Groups 4  
  • 5. Clinical Trial Statistical Considerations Two Separate Assessments Pre-­‐Study  Sample  Size  Determina3on                Post-­‐Study  Sta3s3cal  Analysis   (Output:    number  of  pa3ents)                          (Output:    p  value  result) Assump&ons   Power (80%)                          -­‐                  Probability of sufficient number of patients studied to detect a difference (avoid false negative) §  Assessments   §  Primary  endpoint  (eg,  pa3ent  survival)   §  Sta3s3cal  test  to  determine  p  value  (eg,   modified  log-­‐rank  test  to  compare  Kaplan-­‐ Meier  pa3ent  survival  curves)   [Post  Hoc  Sensi&vity  Analyses]   §           α  value  (≤0.05)                          -­‐                  Probability of result occurring by chance (avoid false positive) §         Difference  to  be  detected   §  Enrollment  period   §  Follow-­‐up  dura3on   [Prespecified  Sta&s&cal  Analysis  Plan]     5      
  • 6. Regulatory Meeting Preparation   § Back  to  Basics   • WHO   • WHAT   • WHERE   • WHY   • HOW     6  
  • 7. Regulatory Preparation: Back to Basics   § WHO    (is going to be involved)   • Iden6fy  individuals  from  the  Regulatory  Agencies  who  will  be     involved  in  interac6ons  so  the  right  company  and  external   experts  are  available  for  mee6ngs  and/or  teleconferences   • Contact  external  experts  as  soon  as  possible  to  ensure  their   availability         7  
  • 8. Regulatory Preparation: Back to Basics   § WHAT  (needs to be done)   • Compile  a  complete  list  of  ac6vi6es  that  need  to  be        accomplished  for  the  mee6ng   • Do  not  overlook  details  which  can  cause  delays  or  inconvenience   such  as  booking  a  sufficient  number  of  hotel  rooms     8  
  • 9. Regulatory Preparation: Back to Basics   § WHERE   (will prep meetings and actual meeting be held)   • Determine  loca6on  of  mee6ngs  early  on  to  facilitate      travel  and  hotel  bookings   • Prepare  for  con6ngencies  such  as  the  possibility  of  extra      aRendees         9  
  • 10. Regulatory Preparation: Back to Basics   § WHY  (the  need  for  a  mee6ng  should  be  asked                      to  provide  clarity  of  mee6ng  goals  and  details  to                      facilitate  prepara6on)                         • Establish  rapport  as  possible  with  Regulatory  Agency  staff  to   assist  with  planning     • Hold  prep  teleconferences  and/or  mee6ngs  to  minimize   disconnects       10  
  • 11. Regulatory Preparation: Back to Basics   § HOW    (will logistics be coordinated to avoid duplication of   activities)                                 • Prepare  a  6me  and  event  schedule  to  delineate      expecta6ons         11  
  • 12. Regulatory Preparation   §   Needs       • Iden6fy  the  goals  for  the  mee6ng     • Understand  how  work  is  distributed     • Foster  collabora6on       12  
  • 13. Regulatory Preparation   §   Details       • Know  the  audience   -­‐    Obtain  informa6on  on  their  exper6se     • Try  to  preempt  an6cipated  ques6ons  in  the  briefing   document   -­‐    Understand  Agency  stance  on  topic(s)  to  be  discussed     13  
  • 14. Drug Development §  Critical Success Factor −  Upfront  planning  to  prevent  problems   14  
  • 15. Drug Development Key Factors in Drug Development - Balance Quality Drug Development Time Cost Align Goals and Incentives for Success 15